返回 Agenda
Session Chair(s)
Shaghig Palanjian, MBA
Vice President, Global Head, R&D QA and Compliance , Shire, United States
Scott Schliebner, MPH
Senior Vice President, Clinical Development Services, TFS Health Science, United States
Speaker(s)
Rare Disease Protocol Development
VP Researhc & Development, Takeda Pharmaceutical Company Limited, United States
Leveraging Informatics to Accelerate Rare Disease Clinical Development
Senior Vice President, Clinical Development Services, TFS Health Science, United States
Clinical Logistics for Rare Disease Trials
Head of Clinical Operations, Synlogic, United States
Overview of FDA Draft Guidance for Industry: Rare Diseases - Common Issues in Drug Development
Associate Director for Rare Diseases, Office of New Drugs, CDER, FDA, United States
Panel Discussion
Associate Director for Rare Diseases, Office of New Drugs, CDER, FDA, United States
David Whiteman, MD
VP Researhc & Development, Takeda Pharmaceutical Company Limited, United States
Scott Schliebner, MPH
Senior Vice President, Clinical Development Services, TFS Health Science, United States
Larry Blankstein, PHD
Head of Clinical Operations, Synlogic, United States